Table 3.
Impact of PCV20 versus PCV15 as SoC over 10 years.
| Outcome | PCV15 | PCV20 | Difference |
|---|---|---|---|
| Cases of IPD | 44,824 | 39,265 | −5,559 |
| Cases of hospitalized pneumonia | 3,357,540 | 3,254,564 | −102,976 |
| Cases of non-hospitalized pneumonia | 11,325,104 | 11,283,803 | −41,301 |
| Cases of complex OM | 35,441 | 33,351 | −2,090 |
| Cases of simple OM | 3,039,726 | 2,886,061 | −153,665 |
| Number of deaths due to disease | 234,806 | 227,540 | −7,266 |
| Payer perspective: total costs | $57,270,492,746 | $55,786,224,862 | −$1,484,267,884 |
| Cost of doses | $909,392,243 | $991,476,031 | $82,083,788 |
| Medical costs | $56,240,055,653 | $54,689,266,231 | −$1,550,789,422 |
| Costs of lifetime sequalae | $121,044,849 | $105,482,600 | −$15,562,249 |
| Societal perspective: total costs | $67,951,242,501 | $66,159,121,040 | −$1,792,121,460 |
| QALYs | 338,990,806 | 339,012,687 | 21,881 |
| QALY loss to Meningitis | 84 | 74 | −10 |
| QALY loss to Bacteremia | 1,120 | 984 | −136 |
| QALY loss to Non-invasive hospitalized pneumonia | 108,660 | 105,490 | −3170 |
| QALY loss to Non-hospitalized pneumonia | 203,575 | 203,543 | −32 |
| QALY loss to Complex OM | 50 | 48 | −2 |
| QALY loss to Simple OM | 4,330 | 4,113 | −217 |
| QALY loss to Deafness | 21 | 18 | −3 |
| QALY loss to Disability | 22 | 19 | −3 |
| Payer Perspective: ICER per QALY | PCV20 Dominant | ||
| Societal Perspective: ICER per QALY | PCV20 Dominant |
Abbreviations: ICER = incremental cost-effectiveness ratio; IPD = invasive pneumococcal disease; OM = otitis media; QALY = quality-adjusted life years; SoC = standard of care.
Costs are expressed in Canadian dollars.